Skip to main content

Advertisement

SpringerLink
Log in

Update analysis of studies on the MMP-9 −1562 C>T polymorphism and cancer risk

  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

Polymorphisms in the matrix metalloproteinase (MMP) gene have been hypothesized to be functional and may contribute to genetic susceptibility to cancers. The common sequence variation in MMP-9 −1562 C>T (rs3918242), has been involved in cancer risk. However, results of the related published studies were somewhat controversial and underpowered in general. To clarify the role of MMP-9 −1562 C>T genotype in global cancer, we performed a meta-analysis of all the available published studies involving 4,124 cancer patients and 4,728 control subjects. The overall results indicated that there was no major association of the variant on cancer risk. However, stratified analysis by cancer type showed that the MMP-9 −1562 C>T polymorphism has a lower risk in colorectal cancer (OR = 0.80, 95%CI = 0.66–0.96, P heterogeneity = 0.391) and lung cancer (OR = 0.70, 95%CI = 0.51–0.96, P heterogeneity = 0.959) by allelic contrast. Furthermore, association of the MMP-9 −1562 C>T polymorphism and cancer risk was also observed in hospital-based studies under the dominant genetic model (OR = 0.87, 95%CI = 0.78–0.97, P heterogeneity = 0.355), allelic contrast (OR = 0.85, 95%CI = 0.75–0.96, P heterogeneity = 0.271) and heterozygote comparison (OR = 0.89, 95%CI = 0.79–0.99, P heterogeneity = 0.402). This pooled analysis showed evidence that the MMP-9 −1562 C>T polymorphism may decrease both the colorectal and lung cancer risk. Further prospective studies with larger numbers of participants worldwide are required to evaluate the association in more detail.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Wolf K, Friedl P (2009) Mapping proteolytic cancer cell-extracellular matrix interfaces. Clin Exp Metastasis 26:289–298

    Article  PubMed  CAS  Google Scholar 

  2. Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T (2003) Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 253:269–285

    Article  PubMed  CAS  Google Scholar 

  3. Malemud CJ (2006) Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci 11:1696–1701

    Article  PubMed  CAS  Google Scholar 

  4. Van Saun MN, Matrisian LM (2006) Matrix metalloproteinases and cellular motility in development and disease. Birth Defects Res C Embryo Today 78:69–79

    Article  Google Scholar 

  5. Deryugina EI, Quigley JP (2006) Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25:9–34

    Article  PubMed  CAS  Google Scholar 

  6. Decock J, Paridaens R, Ye S (2008) Genetic polymorphisms of matrix metalloproteinases in lung, breast and colorectal cancer. Clin Genet 73:197–211

    Article  PubMed  CAS  Google Scholar 

  7. Gum R, Lengyel E, Juarez J, Chen JH, Sato H, Seiki M, Boyd D (1996) Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. J Biol Chem 271:10672–10680

    Article  PubMed  CAS  Google Scholar 

  8. Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N, Ross S (2001) Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 7:3113–3119

    PubMed  CAS  Google Scholar 

  9. Van Kempen LC, Coussens LM (2002) MMP9 potentiates pulmonary metastasis formation. Cancer Cell 2:251–252

    Article  PubMed  Google Scholar 

  10. Coussens LM, Tinkle CL, Hanahan D, Werb Z (2000) MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103:481–490

    Article  PubMed  CAS  Google Scholar 

  11. Zhang B, Ye S, Herrmann SM, Eriksson P, de Maat M, Evans A, Arveiler D, Luc G, Cambien F, Hamsten A, Watkins H, Henney AM (1999) Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 99:1788–1794

    PubMed  CAS  Google Scholar 

  12. Kader AK, Shao L, Dinney CP, Schabath MB, Wang Y, Liu J, Gu J, Grossman HB, Wu X (2006) Matrix metalloproteinase polymorphisms and bladder cancer risk. Cancer Res 66:11644–11648

    Article  PubMed  CAS  Google Scholar 

  13. Elander N, Söderkvist P, Fransén K (2006) Matrix metalloproteinase (MMP) -1, -2, -3 and -9 promoter polymorphisms in colorectal cancer. Anticancer Res 26:791–795

    PubMed  CAS  Google Scholar 

  14. Woo M, Park K, Nam J, Kim JC (2007) Clinical implications of matrix metalloproteinase-1, -3, -7, -9, -12, and plasminogen activator inhibitor-1 gene polymorphisms in colorectal cancer. J Gastroenterol Hepatol 22:1064–1070

    Article  PubMed  CAS  Google Scholar 

  15. Kubben FJ, Sier CF, Meijer MJ, van den Berg M, van der Reijden JJ, Griffioen G, van de Velde CJ, Lamers CB, Verspaget HW (2006) Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer. Br J Cancer 95:744–751

    Article  PubMed  CAS  Google Scholar 

  16. Li Y, Jin X, Kang S, Wang Y, Du H, Zhang J, Guo W, Wang N, Fang S (2006) Polymorphisms in the promoter regions of the matrix metalloproteinases-1, -3, -7, and -9 and the risk of epithelial ovarian cancer in China. Gynecol Oncol 101:92–96

    Article  PubMed  CAS  Google Scholar 

  17. Xing LL, Wang ZN, Jiang L, Zhang Y, Xu YY, Li J, Luo Y, Zhang X (2007) Matrix metalloproteinase-9 –1562C>T polymorphism may increase the risk of lymphatic metastasis of colorectal cancer. World J Gastroenterol 13:4626–4629

    Article  PubMed  CAS  Google Scholar 

  18. Tu HF, Wu CH, Kao SY, Liu CJ, Liu TY, Lui MT (2007) Functional −1562 C-to-T polymorphism in matrix metalloproteinase-9 (MMP-9) promoter is associated with the risk for oral squamous cell carcinoma in younger male areca users. J Oral Pathol Med 36:409–414

    Article  PubMed  CAS  Google Scholar 

  19. Nasr HB, Mestiri S, Chahed K, Bouaouina N, Gabbouj S, Jalbout M, Chouchane L (2007) Matrix metalloproteinase-1 (−1607) 1G/2G and -9 (−1562) C/T promoter polymorphisms: susceptibility and prognostic implications in nasopharyngeal carcinomas. Clin Chim Acta 384:57–63

    Article  PubMed  Google Scholar 

  20. Awakura Y, Ito N, Nakamura E, Takahashi T, Kotani H, Mikami Y, Manabe T, Kamoto T, Habuchi T, Ogawa O (2006) Matrix metalloproteinase-9 polymorphisms and renal cell carcinoma in a Japanese population. Cancer Lett 241:59–63

    Article  PubMed  CAS  Google Scholar 

  21. Matsumura S, Oue N, Nakayama H, Kitadai Y, Yoshida K, Yamaguchi Y, Imai K, Nakachi K, Matsusaki K, Chayama K, Yasui W (2005) A single nucleotide polymorphism in the MMP-9 promoter affects tumor progression and invasive phenotype of gastric cancer. J Cancer Res Clin Oncol 131:19–25

    Article  PubMed  CAS  Google Scholar 

  22. Sugimoto M, Yoshida S, Kennedy S, Deguchi M, Ohara N, Maruo T (2006) Matrix metalloproteinase-1 and -9 promoter polymorphisms and endometrial carcinoma risk in a Japanese population. J Soc Gynecol Investig 13:523–529

    PubMed  CAS  Google Scholar 

  23. Bayramoglu A, Gunes HV, Metintas M, Degirmenci I, Mutlu F, Alatas F (2009) The association of MMP-9 enzyme activity, MMP-9 C1562T polymorphism, and MMP-2 and -9 and TIMP-1, -2, -3, and -4 gene expression in lung cancer. Genet Test Mol Biomarkers 13:671–678

    Article  PubMed  CAS  Google Scholar 

  24. Lu Z, Cao Y, Wang Y, Zhang Q, Zhang X, Wang S, Li Y, Xie H, Jiao B, Zhang J (2007) Polymorphisms in the matrix metalloproteinase-1, 3, and 9 promoters and susceptibility to adult astrocytoma in northern China. J Neurooncol 85:65–73

    Article  PubMed  CAS  Google Scholar 

  25. Lei H, Hemminki K, Altieri A, Johansson R, Enquist K, Hallmans G, Lenner P, Forsti A (2007) Promoter polymorphisms in matrix metalloproteinases and their inhibitors: few associations with breast cancer susceptibility and progression. Breast Cancer Res Treat 103:61–69

    Article  PubMed  CAS  Google Scholar 

  26. Roehe AV, Frazzon AP, Agnes G, Damin AP, Hartman AA, Graudenz MS (2007) Detection of polymorphisms in the promoters of matrix metalloproteinases 2 and 9 genes in breast cancer in South Brazil: preliminary results. Breast Cancer Res Treat 102:123–124

    Article  PubMed  CAS  Google Scholar 

  27. Sfar S, Saad H, Mosbah F, Gabbouj S, Chouchane L (2007) TSP1 and MMP9 genetic variants in sporadic prostate cancer. Cancer Genet Cytogenet 172:38–44

    Article  PubMed  CAS  Google Scholar 

  28. Okamoto K, Ishida C, Ikebuchi Y, Mandai M, Mimura K, Murawaki Y, Yuasa I (2010) The genotypes of IL-1 beta and MMP-3 are associated with the prognosis of HCV-related hepatocellular carcinoma. Intern Med 49:887–895

    Article  PubMed  Google Scholar 

  29. Park KS, Kim SJ, Kim KH, Kim JC (2011) Clinical characteristics of TIMP2, MMP2, and MMP9 gene polymorphisms in colorectal cancer. J Gastroenterol Hepatol 26:391–397

    Article  PubMed  CAS  Google Scholar 

  30. Rollin J, Régina S, Vourc’h P, Iochmann S, Bléchet C, Reverdiau P, Gruel Y (2007) Influence of MMP-2 and MMP-9 promoter polymorphisms on gene expression and clinical outcome of non-small cell lung cancer. Lung Cancer 56:273–280

    Article  PubMed  Google Scholar 

  31. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188

    Article  PubMed  CAS  Google Scholar 

  32. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748

    PubMed  CAS  Google Scholar 

  33. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560

    Article  PubMed  Google Scholar 

  34. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634

    Article  PubMed  CAS  Google Scholar 

  35. Peng B, Cao L, Ma X, Wang W, Wang D, Yu L (2010) Meta-analysis of association between matrix metalloproteinases 2, 7 and 9 promoter polymorphisms and cancer risk. Mutagenesis 25:371–379

    Article  PubMed  CAS  Google Scholar 

  36. Wang Y, Fang S, Wei L, Wang R, Jin X, Wen D, Li Y, Guo W, Wang N, Zhang J (2005) No association between the C-1562T polymorphism in the promoter of matrix metalloproteinase-9 gene and non-small cell lung carcinoma. Lung Cancer 49:155–161

    Article  PubMed  Google Scholar 

  37. Zhai Y, Qiu W, Dong XJ, Zhang XM, Xie WM, Zhang HX, Yuan XY, Zhou GQ, He FC (2007) Functional polymorphisms in the promoters of MMP-1, MMP-2, MMP-3, MMP-9, MMP-12 and MMP-13 are not associated with hepatocellular carcinoma risk. Gut 56:445–447

    Article  PubMed  Google Scholar 

  38. Vairaktaris E, Serefoglou Z, Avgoustidis D, Yapijakis C, Critselis E, Vylliotis A, Spyridonidou S, Derka S, Vassiliou S, Nkenke E, Patsouris E (2009) Gene polymorphisms related to angiogenesis, inflammation and thrombosis that influence risk for oral cancer. Oral Oncol 45:247–253

    Article  PubMed  CAS  Google Scholar 

  39. Pharoah PD, Dunning AM, Ponder BA, Easton DF (2004) Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer 4:850–860

    Article  PubMed  CAS  Google Scholar 

  40. Ioannidis JP (1998) Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. JAMA 279:281–286

    Article  PubMed  CAS  Google Scholar 

  41. Wei Q, Cheng L, Amos CI, Wang LE, Guo Z, Hong WK, Spitz MR (2000) Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst 92:1764–1772

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The research was supported by grants from the National Natural Science Foundation of China (No. 30872596).

Author information

Authors and Affiliations

  1. Department of Urology, Changzhou No. 2 People’s Hospital Affiliated to Nanjing Medical University, Changzhou, 213003, Jiangsu Province, China

    Li-Feng Zhang, Wei-Min Liu & Jian-Gang Zou

  2. Department of Urology, Third Affiliated Hospital of Nantong University, 585 Xingyuan Road, Wuxi, 214041, China

    Yuan-Yuan Mi

  3. Department of Urology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, China

    Qiang Cao, Wei Wang, Chao Qin, Jun-Feng Wei, Yao-Jun Zhou, Yong-Fei Li, Min Tang & Wei Zhang

Authors
  1. Li-Feng Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuan-Yuan Mi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qiang Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wei Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chao Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jun-Feng Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yao-Jun Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yong-Fei Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Min Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Wei-Min Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Wei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Jian-Gang Zou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Wei Zhang or Jian-Gang Zou.

Additional information

Li-Feng Zhang, Yuan-Yuan Mi and Qiang Cao contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhang, LF., Mi, YY., Cao, Q. et al. Update analysis of studies on the MMP-9 −1562 C>T polymorphism and cancer risk. Mol Biol Rep 39, 3435–3441 (2012). https://doi.org/10.1007/s11033-011-1115-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-011-1115-5

Keywords

Search

Navigation